Hear the latest on PCSK9 inhibitors, cardiorenal benefits of GLP-1 drugs, and other clinical research in this interview with Katie Berlacher, MD, MS, chair of this year's annual ACC meeting. Related Content: PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Why GLP-1 Drugs Affect Patients Differently
Treating Methamphetamine Use Disorder With an Antidepressant
Cicada, the SARS-CoV-2 Variant With a Surprising Trajectory
Cancer-Treating Vaccines Are on the Horizon
Free AI-powered recaps of JAMA Medical News and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.